Literature DB >> 17764927

Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe.

Diego Serraino1, Pierluca Piselli, Ghil Busnach, Patrizia Burra, Franco Citterio, Eloisa Arbustini, Umberto Baccarani, Emanuela De Juli, Ubaldo Pozzetto, Stefania Bellelli, Jerry Polesel, Christian Pradier, Luigino Dal Maso, Claudio Angeletti, Maria Patrizia Carrieri, Giovanni Rezza, Silvia Franceschi.   

Abstract

This investigation highlighted the risk of cancer in 8074 HIV-infected people and in 2875 transplant recipients in Italy and France. Observed and expected numbers of cancer were compared through sex- and age-standardised incidence ratios (SIRs) and 95% confidence intervals (CIs). After 15 years of follow-up, the cumulative probability of cancer was 14.7% in transplant recipients and 13.3% in HIV-positives. The SIRs for all cancers were 9.8 in HIV-positives and 2.2 in transplants. Kaposi's sarcoma (SIR=451 in HIV-positives, 125 in transplants) and non-Hodgkin lymphoma (SIR=62 and 11.1, respectively) were the most common cancers. A significantly increased SIR for liver cancer also emerged in both groups. The risk of lung cancer was significantly elevated in heart transplant recipients (SIR=2.8), and of borderline statistical significance in HIV-positive people (95% CI:0.9-2.8). Immune depression entails a two-fold increased overall risk of cancers, mainly related to cancers associated with a viral aetiology.

Entities:  

Mesh:

Year:  2007        PMID: 17764927     DOI: 10.1016/j.ejca.2007.07.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  47 in total

1.  Deacetylation by SIRT1 Reprograms Inflammation and Cancer.

Authors:  Tie Fu Liu; Charles E McCall
Journal:  Genes Cancer       Date:  2013-03

Review 2.  HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.

Authors:  Khatiya Chelidze; Cristina Thomas; Aileen Yenting Chang; Esther Ellen Freeman
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

Review 3.  Lung cancer in HIV Infection.

Authors:  Deepthi Mani; Missak Haigentz; David M Aboulafia
Journal:  Clin Lung Cancer       Date:  2011-07-29       Impact factor: 4.785

4.  Current status of immunotherapy for the treatment of lung cancer.

Authors:  Sanjay Murala; Vamsi Alli; Daniel Kreisel; Andrew E Gelman; Alexander S Krupnick
Journal:  J Thorac Dis       Date:  2010-12       Impact factor: 2.895

5.  Central memory CD8+ T lymphocytes mediate lung allograft acceptance.

Authors:  Alexander Sasha Krupnick; Xue Lin; Wenjun Li; Ryuiji Higashikubo; Bernd H Zinselmeyer; Hollyce Hartzler; Kelsey Toth; Jon H Ritter; Mikhail Y Berezin; Steven T Wang; Mark J Miller; Andrew E Gelman; Daniel Kreisel
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

6.  A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals.

Authors:  Meredith S Shiels; Stephen R Cole; Gregory D Kirk; Charles Poole
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

Review 7.  Lung cancer: a rare indication for, but frequent complication after lung transplantation.

Authors:  Dirk Van Raemdonck; Robin Vos; Jonas Yserbyt; Herbert Decaluwe; Paul De Leyn; Geert M Verleden
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

8.  Hodgkin's Disease in Patients with HIV Infection.

Authors:  Michele Spina; Antonino Carbone; Annunziata Gloghini; Diego Serraino; Massimiliano Berretta; Umberto Tirelli
Journal:  Adv Hematol       Date:  2010-09-23

Review 9.  The evolving scenario of non-AIDS-defining cancers: challenges and opportunities of care.

Authors:  Emanuela Vaccher; Diego Serraino; Antonino Carbone; Paolo De Paoli
Journal:  Oncologist       Date:  2014-06-26

10.  Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995-2002).

Authors:  V Ascoli; G Minelli; M Kanieff; R Crialesi; L Frova; S Conti
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.